孕三烯酮与左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床疗效及安全性分析

目的]探讨孕三烯酮与左炔诺孕酮宫内缓释系统(LNG-IUS)治疗子宫腺肌病的临床疗效及安全性.方法]选取2014年2月至2016年3月本院门诊收治的子宫腺肌病患者168例,采用随机数字表法分为观察组与对照组,观察组采用LNG-IUS治疗,对照组采用孕三烯酮治疗,比较两组患者治疗前后的痛经程度、子宫体积、子宫内膜厚度、月经量、血红蛋白水平及不良反应.结果]与治疗前相比,两组患者治疗后痛经程度及月经过多症状均显著缓解,血红蛋白水平均显著升高,且观察组患者痛经程度、月经过多及贫血症状改善更显著(P<0.05);与治疗前及治疗后对照组对比,观察组治疗后患者的子宫内膜厚度及子宫体积显著减小(P<0.05),对照组患者子宫内膜厚度及子宫体积治疗前后无显著差异(P>0.05);与对照组对比,观察组不良反应发生率显著减低(P<0.05).结论]LNG-IUS治疗子宫腺肌病疗效显著优于应用孕三烯酮治疗,且安全性高,值得临床推广应用.

Clinical Efficacy and Safety of Gestrinone and Levonorgestrel-Releasing Intrauterine System ( LNG-IUS) in Treatment of Adenomyosis

Objective]To discuss the clinical efficacy and safety of gestrinone and levonorgestrel-releasing in-trauterine system ( LNG-IUS) in the treatment of adenomyosis. Methods]One hundred and sixty-eight cases of ade-nomyosis in our hospital from February 2014 to March 2016 were selected and divided into the observation group and the control group by random number table method. The observation group was treated with LNG-IUS, while the control group with gestrinone. The degree of dysmenorrhea, uterine volume, endometrial thickness, menstrual volume, hemo-globin levels and adverse reactions were compared between the two groups before and after treatment.Results] Com-pared with the conditions before treatment, dysmenorrhea and menorrhagia of the two groups of patients after treatment were significantly relieved. Hemoglobin levels were significantly increased, and the dysmenorrhea, menorrhagia and anemia symptoms of the observation group were improved ( P<0.05);Compared with the control group before treat-ment, the endometrial thickness and uterine volume of the observation group after treatment were significantly reduced ( P<0.05);there was no significant difference in endometrial thickness and uterine volume in the control group be-fore and after treatment ( P>0.05);Compared with the control group, the incidence of adverse reactions was obvi-ously lower in the observation group ( P<0.05) .Conclusion]The effect of LNG-IUS in treatment of adenomyosis is significantly better than that of gestrinone, and it is safe and worthy of clinical application.